Table 1.
Demographic and clinical characteristics | Cases (48) | Controls (48) | P value | |
---|---|---|---|---|
Age (Years) Median | 36.5 (17.2-71.2) | 34.5 (18.2-76.1) | 0.4479 | |
Sex | Female | 22 (45.8%) | 22 (45.8%) | 1.000 |
Male | 26 (54.2%) | 26 (54.2%) | ||
Ethnicity | Hispanic | 3 (6.3%) | 4 (8.3%) | 0.4553 |
Non-Hispanic | 38 (79.2%) | 41 (85.4%) | ||
Unknown | 7 (14.6%) | 3 (6.3%) | ||
Race | Hispanic American | 1(2.1%) | 2 (4.2%) | 1.000 |
Indian subcontinent | 1(2.1%) | 0 (0.0%) | ||
Unknown | 1(2.1%) | 1 (2.1%) | ||
White | 45 (93.8%) | 45 (93.8%) | ||
BSA (m2) Median (range) | 2.0 (1.5- 2.5) | 1.89 (1.5- 2.4) | 0.0648 | |
Alliance ALL Protocol | 10102 | 25 (52.1%) | 25 (52.1%) | 1.000 |
10403 | 9 (18.8%) | 9 (18.8%) | ||
19802 | 14 (29.2%) | 14 (29.2%) | ||
Highest Neuropathy Grade | 0 | 0 | 11 | |
1 | 0 | 37 | ||
2 | 29 | 0 | ||
3 | 17 | 0 | ||
4 | 2 | 0 | ||
Vincristine Cumulative Dose (mg/m2)* Median (range) | 5.7 (1.3- 30.4) | 10.4 (2.1- 46.8) | 0.0008 |
There was no difference in the cumulative dosage of vincristine in cases and controls, when assessed at the time when neuropathy was documented in the cases.